News

EicOsis Successfully Completes Phase 1a Clinical Trial of EC5026

November 17, 2020

Tetra Therapeutics Announces Positive Topline Results from Phase 2 Study of BPN14770 in Patients with Fragile X Syndrome

November 02, 2020

Three members of one of the intellectual sports teams use an MR-compatible communicator system within the setup for the main experiment. The photograph is published with the permission of the participants. Credit: Shpurov et al.

Is the "Social Brain" a Separate System?

October 19, 2020

Lin BioScience, the parent company of Belite Bio raises $30 million in its rights issue to support LBS-008’s phase 3 clinical trial to treat Stargardt Disease

September 16, 2020

W-S startup lands federal grant to support development of medications for cocaine addiction

July 28, 2020

Belite Bio Announces Positive Results from Phase 1 Clinical Trials of LBS-008

July 20, 2020

EicOsis EC5026 Granted Fast Track Designation by FDA for Neuropathic Pain

April 09, 2020

EicOsis Announces FDA Acceptance of IND Application for EC5026, the First Soluble Epoxide Hydrolase Inhibitor to Treat Pain

October 10, 2019

Drug may protect against Alzheimer’s symptoms

September 10, 2019

Tetra Discovery Partners Initiates Phase 2 Clinical Trial of BPN14770 in Patients with Early Alzheimer’s Disease

May 01, 2019